MA56074B1 - Anticorps contre le sars-cov-2 - Google Patents

Anticorps contre le sars-cov-2

Info

Publication number
MA56074B1
MA56074B1 MA56074A MA56074A MA56074B1 MA 56074 B1 MA56074 B1 MA 56074B1 MA 56074 A MA56074 A MA 56074A MA 56074 A MA56074 A MA 56074A MA 56074 B1 MA56074 B1 MA 56074B1
Authority
MA
Morocco
Prior art keywords
cov
antibodies against
formula
compound represented
against sars
Prior art date
Application number
MA56074A
Other languages
English (en)
Other versions
MA56074A (fr
Inventor
Davide Corti
Florian A Lempp
Amalio Telenti
Katja Fink
Martina Beltramello
Elisabetta Cameroni
Dora Pinto
Gyorgy Snell
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of MA56074A publication Critical patent/MA56074A/fr
Publication of MA56074B1 publication Critical patent/MA56074B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne l'utilisation d'un composé représenté par la formule (i) ou de ses sels pharmaceutiquement acceptables dans la préparation de médicaments pour prévenir ou traiter les maladies infectieuses à coronavirus. Le composé représenté par la formule (i) est utilisé pour traiter les patients atteints d'une pneumonie causée par un nouveau coronavirus, et présente des avantages évidents en ce qui concerne le rapport de conversion négative du test d'acide nucléique viral, le cours de conversion négative et le temps de guérison et de sortie de l'hôpital.
MA56074A 2020-02-26 2021-02-25 Anticorps contre le sars-cov-2 MA56074B1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202062981984P 2020-02-26 2020-02-26
US202062982661P 2020-02-27 2020-02-27
US202062987298P 2020-03-09 2020-03-09
US202062989522P 2020-03-13 2020-03-13
US202062990369P 2020-03-16 2020-03-16
US202062992082P 2020-03-19 2020-03-19
US202062994235P 2020-03-24 2020-03-24
US202063001204P 2020-03-27 2020-03-27
US202063003214P 2020-03-31 2020-03-31
US202063005206P 2020-04-03 2020-04-03
US202063010589P 2020-04-15 2020-04-15
US202063011971P 2020-04-17 2020-04-17
US202063014024P 2020-04-22 2020-04-22
US202063023788P 2020-05-12 2020-05-12
US202063025133P 2020-05-14 2020-05-14
US202063039813P 2020-06-16 2020-06-16
US202063043653P 2020-06-24 2020-06-24
US202063050331P 2020-07-10 2020-07-10
US202063052810P 2020-07-16 2020-07-16

Publications (2)

Publication Number Publication Date
MA56074A MA56074A (fr) 2022-04-06
MA56074B1 true MA56074B1 (fr) 2023-11-30

Family

ID=74758682

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56074A MA56074B1 (fr) 2020-02-26 2021-02-25 Anticorps contre le sars-cov-2

Country Status (26)

Country Link
US (3) US11168128B2 (fr)
EP (2) EP4245373A3 (fr)
JP (2) JP7275405B2 (fr)
KR (1) KR20220164465A (fr)
AU (2) AU2021227687B2 (fr)
BR (1) BR112022017048A2 (fr)
CA (1) CA3158752C (fr)
CL (1) CL2022002335A1 (fr)
CO (1) CO2022013525A2 (fr)
DK (1) DK3872091T5 (fr)
ES (1) ES2954629T3 (fr)
FI (1) FI3872091T3 (fr)
HR (1) HRP20231031T1 (fr)
HU (1) HUE062777T2 (fr)
IL (1) IL295801A (fr)
LT (1) LT3872091T (fr)
MA (1) MA56074B1 (fr)
MX (1) MX2022010537A (fr)
PL (1) PL3872091T3 (fr)
PT (1) PT3872091T (fr)
RS (1) RS64645B1 (fr)
SG (1) SG11202110145SA (fr)
SI (1) SI3872091T1 (fr)
SM (1) SMT202300397T1 (fr)
TW (1) TWI859420B (fr)
WO (1) WO2021173753A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574017A1 (fr) 2017-01-27 2019-12-04 Kymab Limited Anticorps anti-opg
AU2020356407A1 (en) * 2019-09-25 2022-04-07 Universität Stuttgart Binding modules comprising modified EHD2 domains
FI4045533T3 (fi) * 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
MY197648A (en) 2020-04-02 2023-06-30 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
TW202204397A (zh) 2020-04-10 2022-02-01 美商亞得捷歐治療公司 對冠狀病毒s蛋白質具特異性之化合物及其用途
KR20230019166A (ko) 2020-06-03 2023-02-07 리제너론 파아마슈티컬스, 인크. 항-SARS-CoV-2 스파이크 당단백질 항체를 이용한 SARS-CoV-2 감염 및 COVID-19 치료 또는 예방 방법
AU2021288203A1 (en) * 2020-06-12 2023-01-19 Vir Biotechnology, Inc. Antibody therapies for SARS-CoV-2 infection
AU2021305067A1 (en) 2020-07-06 2023-02-09 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting SARS-CoV-2
CA3183367A1 (fr) * 2020-07-06 2022-01-13 Gevorg GRIGORYAN Molecules de liaison a l'antigene ciblant le sars-cov-2
CN116528897A (zh) 2020-08-26 2023-08-01 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
WO2022054068A1 (fr) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Anticorps pour la prévention, le traitement et la détection d'une infection à coronavirus
US20220091132A1 (en) * 2020-09-22 2022-03-24 Becton, Dickinson And Company Cell-based assay for detection of antibodies in a sample
EP4228697A4 (fr) 2020-10-16 2025-01-01 Invisishield Technologies Ltd. Compositions pour la prévention ou le traitement d'infections virales et d'autres infections microbiennes
US12109237B2 (en) * 2020-12-15 2024-10-08 Rutgers, The State University Of New Jersey S309 chimeric antigen receptors and methods of use
EP4370210A1 (fr) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anticorps anti-glycoprotéine de spicule du sars-cov-2 et fragments de liaison à l'antigène
WO2023001736A1 (fr) 2021-07-19 2023-01-26 Universität Für Bodenkultur Wien Anticorps igg3 anti-sars-cov-2 modifiés
WO2023034871A1 (fr) * 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Thérapies par anticorps à haute concentration contre infection par sars-cov-2
US20240400652A1 (en) * 2021-09-01 2024-12-05 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023039442A1 (fr) * 2021-09-08 2023-03-16 Vir Biotechnology, Inc. Polythérapies à base d'anticorps à large spectre de neutralisation pour infection par sars-cov-2
WO2023039540A2 (fr) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions et procédés pour déterminer des réponses immunitaires humorales contre des coronavirus saisonniers et prédire l'efficacité de ciblage de spicule du sars-cov-2, gravité de maladie covid-19, et pour permettre des interventions
WO2023044397A1 (fr) * 2021-09-15 2023-03-23 The Board Of The Trustees Of The University Of Illinois Récepteurs modifiés et anticorps monoclonaux contre les coronavirus et leurs utilisations
WO2023046057A1 (fr) * 2021-09-24 2023-03-30 南京金斯瑞生物科技有限公司 Anticorps monoclonal dirigé contre le mutant l452r de protéine de spicule de sars-cov-2 et son utilisation
WO2023056522A1 (fr) * 2021-10-07 2023-04-13 Seqirus Pty Ltd Anticorps anti-sars-cov-2 et leurs utilisations ii
WO2023086827A1 (fr) * 2021-11-09 2023-05-19 Rhode Island Hospital Prédiction d'anticorps contre la covid-19 parmi des survivants avec séquençage d'arn profond
EP4433613A1 (fr) 2021-11-15 2024-09-25 VIR Biotechnology, Inc. Substituts virologiques et moléculaires de réponse à l'anticorps neutralisant le sars-cov-2 sotrovimab
WO2023094980A1 (fr) * 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Anticorps contre le coronavirus
CN114107223B (zh) * 2021-11-25 2024-03-26 湖北省疾病预防控制中心（湖北省预防医学科学院） 利用TPCK胰酶提高SARS-CoV-2病毒细胞培养滴度的方法
WO2023122211A2 (fr) * 2021-12-21 2023-06-29 Duke University Anticorps du coronavirus et leurs utilisations
EP4460516A2 (fr) * 2022-01-03 2024-11-13 Twist Bioscience Corporation Anticorps bispécifiques du sars-cov-2 et procédés d'utilisation
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン
CN116444656B (zh) * 2022-01-10 2023-09-22 东莞市朋志生物科技有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法
TWI868567B (zh) * 2022-01-26 2025-01-01 中央研究院 冠狀病毒之特異性抗體及其用途
WO2023150307A2 (fr) * 2022-02-03 2023-08-10 Abpro Corporation Compositions et méthodes contre un virus
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023201256A1 (fr) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. Thérapies par anticorps à haute dose contre une infection par le sars-cov-2
CA3256034A1 (fr) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions pour prévenir ou traiter des infections par la grippe
CA3256035A1 (fr) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions pour prévenir ou traiter des infections à coronavirus
EP4519310A1 (fr) 2022-05-06 2025-03-12 Generate Biomedicines, Inc. Molécules de liaison à l'antigène ciblant le sars-cov-2
WO2023224714A1 (fr) * 2022-05-16 2023-11-23 Lawrence Livermore National Security, Llc Anticorps thérapeutiques et prophylactiques réparés contre des variants du sars-cov-2
KR20240008997A (ko) * 2022-07-12 2024-01-22 (재) 스크립스코리아항체연구원 사스-코로나 바이러스 2 중화 항체
WO2024058987A2 (fr) * 2022-09-14 2024-03-21 Merck Sharp & Dohme Llc Polypeptides efficaces contre de multiples coronavirus
AU2023375894A1 (en) 2022-11-13 2025-05-22 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
WO2024112818A1 (fr) * 2022-11-22 2024-05-30 Humabs Biomed Sa Anticorps anti-sars-cov-2 modifiés et leurs utilisations

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004024750A2 (fr) 2002-09-13 2004-03-25 Dyax Corporation Ligands liant cd44
EP1597280B2 (fr) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
CA2521856A1 (fr) 2003-04-08 2004-10-21 Coronovative B.V. Sras
EP1644414B1 (fr) 2003-07-22 2015-01-14 Crucell Holland B.V. Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
US7396914B2 (en) 2003-08-04 2008-07-08 University Of Massachusetts SARS nucleic acids, proteins, antibodies, and uses thereof
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
US7553944B2 (en) 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2652728A1 (fr) 2006-05-19 2008-05-22 Amgen Inc. Anticorps au coronavirus sras
CN101522717A (zh) 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
CA2678628A1 (fr) 2007-03-06 2008-09-12 Symphogen A/S Anticorps recombinants pour le traitement des infections au virus respiratoire syncytial
WO2009128963A2 (fr) 2008-01-17 2009-10-22 Humab, Llc Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2009097133A2 (fr) 2008-01-30 2009-08-06 Monsanto Technology, Llc Plantes transgéniques présentant des caractéristiques agronomiques améliorées
WO2010107752A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
LT2504364T (lt) 2009-11-24 2017-11-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
KR101299753B1 (ko) 2010-11-19 2013-08-23 주식회사 단바이오텍 소 코로나바이러스 항원 결정기를 포함하는 스파이크 재조합 단백질 및 이에 대한 항체
HUE041900T2 (hu) 2012-01-20 2019-06-28 Genzyme Corp Anti-CXCR3 ellenanyagok
AR090244A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
BR112014028764A2 (pt) 2012-05-18 2017-06-27 Novozymes As mutante isolado, métodos para a obtenção do mutante isolado e de um lactobacillus transformante, e, lactobacillus transformante.
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016073906A2 (fr) 2014-11-06 2016-05-12 Scholar Rock, Inc. Immunoessais liés à des facteurs de croissance transformants
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
WO2016138160A1 (fr) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes du coronavirus du syndrome respiratoire du moyen-orient, anticorps et leur utilisation
EA201792250A1 (ru) 2015-04-10 2018-05-31 Эмджен Инк. Мутеины интерлейкина-2 для роста регуляторных т-клеток
EP3294328A1 (fr) 2015-05-08 2018-03-21 Eureka Therapeutics, Inc. Constructions ciblant les complexes mhc/peptide hpv16-e7 et leurs utilisations
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2017058944A1 (fr) 2015-09-29 2017-04-06 Amgen Inc. Inhibiteurs de l'asgr pour réduire les taux de cholestérol
KR102398425B1 (ko) 2016-03-08 2022-05-16 이나뜨 파르마 에스.에이. Siglec 중화 항체
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018102746A1 (fr) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Molécules de liaison à l'antigène destinées à la tigit
RU2019121662A (ru) 2016-12-16 2021-01-18 Мерк Патент Гмбх Способы использования галектин-3-связывающего белка, обнаруживаемого в моче, для мониторинга тяжести и прогрессирования волчаночного нефрита
EP3574017A1 (fr) 2017-01-27 2019-12-04 Kymab Limited Anticorps anti-opg
CN110914295B (zh) 2017-06-28 2024-08-09 里珍纳龙药品有限公司 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
WO2019024979A1 (fr) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Anticorps à domaines fonctionnels dans la région de coude
CA3072267A1 (fr) 2017-08-09 2019-02-14 University Of Saskatchewan Agents de liaison a her3 et utilisations associees
KR101895228B1 (ko) 2017-08-23 2018-10-30 대한민국 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
CN111133003B (zh) 2017-09-22 2024-01-12 上海药明生物技术有限公司 新型双特异性多肽复合物
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
MY197648A (en) * 2020-04-02 2023-06-30 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021203053A1 (fr) * 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunothérapie ciblant une région conservée dans des coronavirus sras
JP2023523549A (ja) * 2020-04-14 2023-06-06 ヴィア・バイオテクノロジー・インコーポレイテッド ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
JP2023525039A (ja) * 2020-05-08 2023-06-14 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体
WO2021247925A1 (fr) * 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Immunothérapie guidée par une structure dirigée contre le sars-cov-2
AU2021288203A1 (en) * 2020-06-12 2023-01-19 Vir Biotechnology, Inc. Antibody therapies for SARS-CoV-2 infection
CN112062859B (zh) * 2020-07-24 2022-08-09 沣潮医药科技（上海）有限公司 用于病原体清除的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
DK3872091T3 (da) 2023-09-11
KR20220164465A (ko) 2022-12-13
AU2021227687B2 (en) 2023-02-23
EP3872091B1 (fr) 2023-06-14
PT3872091T (pt) 2023-09-19
US20210261650A1 (en) 2021-08-26
TWI859420B (zh) 2024-10-21
US11168128B2 (en) 2021-11-09
PL3872091T3 (pl) 2023-12-27
MA56074A (fr) 2022-04-06
JP2023505613A (ja) 2023-02-09
EP3872091A1 (fr) 2021-09-01
TW202146442A (zh) 2021-12-16
LT3872091T (lt) 2023-10-10
JP2023009046A (ja) 2023-01-19
SI3872091T1 (sl) 2023-12-29
SMT202300397T1 (it) 2024-01-10
DK3872091T5 (da) 2024-08-12
JP7275405B2 (ja) 2023-05-17
SG11202110145SA (en) 2021-10-28
CL2022002335A1 (es) 2023-07-21
ES2954629T3 (es) 2023-11-23
IL295801A (en) 2022-10-01
US11479599B2 (en) 2022-10-25
HUE062777T2 (hu) 2023-12-28
HRP20231031T1 (hr) 2023-12-22
FI3872091T3 (fi) 2023-08-31
AU2023203201A1 (en) 2023-06-15
WO2021173753A1 (fr) 2021-09-02
BR112022017048A2 (pt) 2022-11-16
RS64645B1 (sr) 2023-10-31
US20230331821A1 (en) 2023-10-19
CO2022013525A2 (es) 2022-12-20
MX2022010537A (es) 2022-09-21
EP4245373A3 (fr) 2023-12-20
US20210371504A1 (en) 2021-12-02
CA3158752C (fr) 2023-08-08
EP4245373A2 (fr) 2023-09-20
AU2021227687A1 (en) 2022-10-20
CA3158752A1 (fr) 2021-09-02

Similar Documents

Publication Publication Date Title
MA56074B1 (fr) Anticorps contre le sars-cov-2
MA57574A1 (fr) Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus
Zhou et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation
Staples Jr et al. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival
US6046228A (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
Avidan et al. Low complication rate associated with cesarean section under spinal anesthesia for HIV-1–infected women on antiretroviral therapy
CN102438604B (zh) 高致病性传染性疾病的预防及治疗制剂
MA27348A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
RU2007119390A (ru) Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с
ATE464292T1 (de) Pharmazeutisch aktive sulfonamid-derivate
PT98007A (pt) Processo para a preparacao de aminobenzodiazepinas e de composicoes farmaceuticas que as contem
WO2020114444A1 (fr) Utilisation de diacéréine dans la préparation de médicaments antiviraux et traitement d'infections virales
WO2021164689A1 (fr) Application de nelfinavir dans la préparation d'un médicament pour la prévention et le traitement d'une nouvelle pneumonie à coronavirus
ATE92928T1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
GB1334327A (en) Compositions for and method of combating virus infections
Davis et al. Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid CU1+
CN113648313B (zh) 一种哌嗪取代-2-甲基苄腈类化合物zk-22在制备抗冠状病毒药物中的应用
US5519028A (en) Antiviral preparations
Böttiger et al. Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-fluorothymidine
CA2433237A1 (fr) Utilisation de chloroquine, d'hydroxychloroquine et de derives 4-amino-quinoleiques pour produire un medicament antiretroviral pouvant agir sur des souches sensibles au vih et surdes souches de vih resistantes aux inhibiteurs nucleosidiques et non-nucleosidiques de la transcriptase inverse et aux inhibiteurs de proteases
ES3044837T3 (en) Cysteamine for use in anti-viral therapy
US12508251B2 (en) CD4 mimic compound with anti-HIV activity
US20050059745A1 (en) Antiviral therapy
CA2028758A1 (fr) Utilisation d'une benzodiazepine et d'un derive de la phenylpyrrylcetone
Armbruster HIV-1 infection: recent developments in treatment and current management strategies